IRCT20211004052664N1.

Study name	Evaluation of the efficacy of favipiravir in comparison with standard medication on clinical and laboratory findings of COVID‐19 patients with moderate severity
Methods	Phase 3 block‐randomized, open‐label clinical trial with intervention and control groups (allocation ratio 1:1)
Participants	COVID‐19 confirmed by laboratory testing irrespective of severity of clinical signs or symptoms
Interventions	Favipiravir at a dose of 1600 mg every 12 hours for the first day and then 600 mg every 4 hours for 4 days
Outcomes	Body temperature (time points: Days 1 (start of treatment), 3, 5 and 7); respiratory rate (per minute; time points: Days 1 (start of treatment), 3, 5 and 7); oxygen saturation (time points: Days 1 (start of treatment), 3, 5 and 7).
Starting date	31 October 2021
Contact information	Name: Afshin Bagherzade Phone: +98 21 2263 2554 Email address: dr.bagherzade@yahoo.com
Notes